Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (SERENA-1)

  • End date
    Oct 16, 2023
  • participants needed
  • sponsor
Updated on 24 July 2022


A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)


This is a multicentre dose escalation and expansion, first-in-human study designed to evaluate the safety and tolerability of AZD9833, alone (Parts A and B) or in combination with palbociclib (Parts C and D) or in combination with everolimus (Parts E and F) or in combination with abemaciclib (Parts G and H) or in combination with capivasertib (Parts I and J), in women with endocrine-resistant ER+ HER2- breast cancer that is not amenable to treatment with curative intent.

Condition ER+ HER2- Advanced Breast Cancer
Treatment AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus, AZD9833 with abemaciclib dose escalation, AZD9833 with abemaciclib, AZD9833 with capivasertib
Clinical Study IdentifierNCT03616587
Last Modified on24 July 2022


How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note